These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30976563)

  • 1. Review on gender differences in non-muscle invasive bladder cancer.
    Bilski K; Zapała Ł; Skrzypczyk MA; Oszczudłowski M; Dobruch J
    Transl Androl Urol; 2019 Feb; 8(1):12-20. PubMed ID: 30976563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.
    Dobruch J; Daneshmand S; Fisch M; Lotan Y; Noon AP; Resnick MJ; Shariat SF; Zlotta AR; Boorjian SA
    Eur Urol; 2016 Feb; 69(2):300-10. PubMed ID: 26346676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Uhlig A; Strauss A; Seif Amir Hosseini A; Lotz J; Trojan L; Schmid M; Uhlig J
    Eur Urol Focus; 2018 Dec; 4(6):924-936. PubMed ID: 28888813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-muscle invasive bladder cancer risk stratification.
    Isharwal S; Konety B
    Indian J Urol; 2015; 31(4):289-96. PubMed ID: 26604439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High incidence of independent second malignancies after non-muscle-invasive bladder cancer.
    Zecha H; Schmid HP; Tschopp A; Sulser T; Engeler DS
    Scand J Urol Nephrol; 2011 Sep; 45(4):245-50. PubMed ID: 21443417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value.
    Fang D; Zhang L; Li X; Yu W; Singla N; Zhao G; Xiong G; Song Y; He Q; He Z; Zhou L
    Ann Surg Oncol; 2015 Aug; 22(8):2789-98. PubMed ID: 25564161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of content validity for patient-reported outcome measures used in patients with non-muscle invasive bladder cancer: a systematic review.
    Rutherford C; Patel MI; Tait MA; Smith DP; Costa DSJ; King MT
    Support Care Cancer; 2018 Apr; 26(4):1061-1076. PubMed ID: 29392479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of Life in Non-Muscle-Invasive Bladder Cancer Survivors: A Systematic Review.
    Jung A; Nielsen ME; Crandell JL; Palmer MH; Bryant AL; Smith SK; Mayer DK
    Cancer Nurs; 2019; 42(3):E21-E33. PubMed ID: 29863576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer.
    Li CE; Chien CS; Chuang YC; Chang YI; Tang HP; Kang CH
    Int Urol Nephrol; 2016 Jun; 48(6):993-9. PubMed ID: 26995008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.
    Nielsen ME; Smith AB; Pruthi RS; Guzzo TJ; Amiel G; Shore N; Lotan Y
    BJU Int; 2012 Oct; 110(7):967-72. PubMed ID: 22487336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer.
    Grotenhuis AJ; Ebben CW; Aben KK; Witjes JA; Vrieling A; Vermeulen SH; Kiemeney LA
    Urol Oncol; 2015 Feb; 33(2):65.e9-17. PubMed ID: 25023787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer.
    Lian F; Chen W; Liu Y; Shen L; Fan W; Cui W; Zhao Y; Li J; Wang Y
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1625-1633. PubMed ID: 30900154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
    Soukup V; Čapoun O; Cohen D; Hernández V; Babjuk M; Burger M; Compérat E; Gontero P; Lam T; MacLennan S; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R
    Eur Urol; 2017 Nov; 72(5):801-813. PubMed ID: 28457661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis.
    Richard PO; Ahmad AE; Bashir S; Zlotta A; Bhindi B; Leao R; Nayan M; Mohammed A; Fleshner NE; Kulkarni GS
    Can Urol Assoc J; 2018 Jun; 12(6):203-210. PubMed ID: 29485035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of detection of preoperative urinary soluble Fas expression in predicting the recurrence of non-muscle invasive bladder cancer].
    Yang H; Guo Y; Wang Z; Wang Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Jan; 41(1):24-9. PubMed ID: 26819421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A conceptual framework for patient-reported outcomes in non-muscle invasive bladder cancer.
    Rutherford C; Costa DSJ; King MT; Smith DP; Patel MI
    Support Care Cancer; 2017 Oct; 25(10):3095-3102. PubMed ID: 28451912
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.